证券代码：600518 证券简称：ST康美 编号：临2023-032 康美药业股份有限公司关于康美实业 所持公司部分股份被司法拍卖的进展公告 二、其他相关说明及风险提示 （一）截至本公告日，康美实业持有公司股份 723,176,677 股，占公司总股 本的 5.21%，本次被拍卖的公司股份后续是否二次被拍卖具有不确定性。若拍卖 最终举行，涉及的竞拍、缴款、法院执行法定程序、股权变更过户等环节均存在 一定的不确定性。公司将根据法院执行情况，及时履行相应的信息披露义务。 （二）康美实业持有公司股份被拍卖事项，不会导致公司控股股东及实际控 制人发生变化，亦不会对公司经营活动产生影响。 （三）康美实业已被裁定宣告破产，其持有的公司股份后续将被分批进行公 开处置。公司将及时履行信息披露义务，敬请广大投资者理性投资并注意投资风 险。 1 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 康美药业股份有限公司（以下简称公司）于 2023 年 8 月 16 日披露了《康美 药业关于康美实业所持公司部分股份将被司法拍卖的提示性公告》（公告编号： ...

证券代码：600518 证券简称：ST康美 编号：临2023-031 康美药业股份有限公司 关于召开 2023 年半年度业绩说明会的公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 会议召开时间：2023 年 09 月 14 日（星期四）下午 13:00-14:00 会议召开地点： 上海证券 交 易 所 上 证 路 演 中 心 （ 网址： http://roadshow.sseinfo.com/） 会议召开方式：上证路演中心网络文字互动 投资者可于 2023 年 09 月 07 日（星期四）至 09 月 13 日（星期三）16:00 前登录上证路演中心网站首页点击"提问预征集"栏目或通过公司邮箱 kangmei@kangmei.com.cn 进行提问。公司将在业绩说明会上对投资者普遍关注 的问题进行回答。 康美药业股份有限公司（以下简称公司）已于 2023 年 08 月 19 日发布公司 2023 年半年度报告，为便于广大投资者更全面深入地了解公司 2023 年半年度经 营成果、财务状况，公司计划于 202 ...

康美药业股份有限公司关于全资子公司 收到法院不予受理破产清算裁定的进展公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 公司全资子公司康美中药城（普宁）有限公司收到揭阳中院送达的《民 事上诉状》，深圳中科恒实业有限公司不服揭阳中院做出的裁定，向广东省高 级人民法院提起上诉。 2023 年 8 月 28 日，康美药业股份有限公司（以下简称公司）全资子公司 康美中药城（普宁）有限公司（以下简称普宁中药城或被上诉人）收到广东省 揭阳市中级人民法院（以下简称揭阳中院）送达的《民事上诉状》，深圳中科 恒实业有限公司（以下简称中科恒或上诉人）不服揭阳中院做出的（2023）粤 52 破申 5 号民事裁定书，向广东省高级人民法院（以下简称广东高院）提起上 诉，现将相关情况公告如下： 一、普宁中药城被申请破产清算的基本情况 证券代码：600518 证券简称：ST康美 编号：临2023-030 二、本次事项对公司的影响 若普宁中药城进入破产清算程序，对公司中药城业务收入影响较小，公司 中药城资产规模相应缩小。 截至目前，普宁中 ...

Financial Performance - The company's operating revenue for the first half of 2023 was ¥2,377,001,837.34, representing a 33.62% increase compared to ¥1,778,866,938.39 in the same period last year[14]. - The net profit attributable to shareholders of the listed company was -¥125,858,164.21, an improvement from -¥195,645,914.65 in the previous year[14]. - The net cash flow from operating activities was -¥190,179,871.80, compared to -¥316,747,838.83 in the same period last year[14]. - The total assets at the end of the reporting period were ¥14,587,349,688.80, down 3.47% from ¥15,111,759,138.19 at the end of the previous year[14]. - The net assets attributable to shareholders of the listed company decreased by 1.75% to ¥6,825,462,029.68 from ¥6,947,130,703.24 at the end of the previous year[14]. - The basic earnings per share for the first half of 2023 was -¥0.009, compared to -¥0.014 in the same period last year[15]. - The weighted average return on net assets was -1.83%, slightly improved from -1.99% in the previous year[15]. - The company reported a non-recurring profit of approximately ¥80.27 million for the period, primarily from non-operating income sources such as asset disposals and government subsidies[17]. - The company’s revenue for the first half of 2023 reached ¥2,377,001,837.34, representing a 33.62% increase compared to ¥1,778,866,938.39 in the same period last year[49]. - Operating costs increased by 32.15% to ¥1,961,303,652.22 from ¥1,484,203,044.92, primarily due to the rise in revenue[49]. - Research and development expenses surged by 91.72% to ¥23,578,605.73, reflecting the company's increased investment in R&D projects[49]. - The company reported a net cash flow from operating activities of -¥190,179,871.80, an improvement from -¥316,747,838.83 in the previous year[49]. - Other income rose by 91.62% to ¥36,483,714.88, driven by an increase in government subsidies[51]. - Investment income skyrocketed by 285,176.16% to ¥21,872,550.99, attributed to the disposal of long-term equity investment assets[51]. Industry Position and Strategy - The pharmaceutical industry is increasingly integrated with the "big health" concept, with a focus on innovation and quality improvement, as highlighted by recent government policies[19]. - The company holds a leading position in the Chinese herbal medicine market, with a significant share of its revenue coming from traditional Chinese medicine (TCM) products, particularly herbal pieces[19]. - The company has established nine production bases across various provinces, capable of producing over 1,000 types and more than 20,000 specifications of herbal products[19]. - The company has over 550 patents and software copyrights, demonstrating its strong capability in technological innovation within the TCM sector[19]. - The company is recognized as a national technology innovation demonstration enterprise and a pilot demonstration enterprise for intelligent manufacturing in herbal pieces[19]. - The company’s business model encompasses the entire TCM supply chain, from cultivation and processing to sales and distribution through various channels[20]. - The company is positioned to benefit from the ongoing reforms and investments in the healthcare sector, which are expected to drive growth in the TCM industry[19]. - The company’s focus on integrating modern logistics and e-commerce into its distribution strategy aims to enhance market reach and operational efficiency[20]. - Key products include unique traditional Chinese medicines such as Baoning Banxia Granules and chemical drugs like Acetaminophen Powder, addressing significant market needs in cardiovascular, respiratory, and endocrine fields[21]. - The company has established deep business partnerships with over 1,100 medical institutions and more than 40,000 chain pharmacies nationwide, enhancing its market reach[27]. - The company has implemented a full industry chain integrated operation model, covering everything from raw material planting to sales through various channels including hospitals, OTC, and e-commerce[26]. Research and Development - The company has developed 497 small-scale trial varieties and 199 pilot varieties for traditional Chinese medicine (TCM) formula granules, with 135 varieties completed for market filing[28]. - The company holds over 550 intellectual property rights, including 6 newly authorized invention patents during the reporting period[29]. - The company has submitted technical materials for national processing standards for 9 TCM varieties and contributed to the drafting of national standards for TCM processing[30]. - The company has implemented a quality control model across the entire TCM industry chain, ensuring strict adherence to production standards and quality management[31]. - The company has maintained a record of "0 violations, 0 reports, 0 blacklists" in the industry, receiving positive feedback from hospitals, pharmacies, and consumers[32]. - The company is focusing on high-quality development in line with national strategies, optimizing its organizational structure and enhancing internal controls[34]. - The company is actively promoting innovation in TCM, including the development of formula granules and food-medicine integration products[34]. - The company has invested in advanced detection equipment and established a testing center exceeding 3,100 square meters to ensure product quality[31]. Environmental and Social Responsibility - The company has complied with environmental regulations and has not experienced any environmental pollution incidents during the reporting period[61]. - The company has implemented a self-monitoring plan for pollution discharge and regularly conducts technical testing services[68]. - The company’s environmental protection measures include a comprehensive emergency response plan for environmental incidents[67]. - The company is committed to green operations and has taken measures to prevent environmental pollution and risks[63]. - The company has established a standardized turtle breeding base in collaboration with a local cooperative, benefiting over 140 farmers with an approximate income increase of 20%[73]. - The company has assisted 1,079 registered households in Yunnan Province, helping 171 households and 30 disabled individuals find employment, with a total of approximately 8,360 job opportunities created[73]. - The company has invested over 150,000 yuan in medical resources for grassroots health services during the reporting period[75]. - The company has supported over 8,300 students from Jieyang to pursue higher education through its university student foundation by mid-2023[74]. - The company is committed to enhancing its corporate social responsibility by continuing to promote rural revitalization and poverty alleviation initiatives[76]. Governance and Compliance - The company has established a compliance management system to address increasing regulatory scrutiny in the pharmaceutical industry[57]. - The company commits to maintaining the independence of its business operations and governance structure, ensuring no interference from controlling entities[80]. - There are no significant non-operating fund occupations by controlling shareholders or related parties during the reporting period[81]. - The company has not engaged in any significant litigation or arbitration matters during the reporting period[84]. - The company has not provided any guarantees that are overdue or have not been fulfilled during the reporting period[87]. - The company has a complete and independent business process and decision-making capability for its subsidiaries[80]. - The company has a three-year shareholder return plan for 2023-2025 approved at the annual general meeting[59]. Shareholder Information - The total number of common shareholders at the end of the reporting period is 200,443[91]. - The largest shareholder, Guangdong Shennongshi Enterprise Management Partnership, holds 3,509,413,788 shares, accounting for 25.31% of total shares[92]. - The second largest shareholder, Kangmei Industrial Investment Holdings, holds 723,176,677 shares, representing 5.21%[92]. - The total number of shares held by the top ten shareholders includes significant pledges, with the largest pledge being 715,509,782 shares by Kangmei Industrial Investment Holdings[92]. - The company has not reported any changes in share capital structure during the reporting period[90]. - There are no significant changes in the number of restricted shares that can be traded[94]. Financial Reporting and Accounting - The financial statements have been approved by the board of directors on August 17, 2023[123]. - The company has no significant factors affecting its ability to continue as a going concern within the next 12 months[126]. - The financial statements are prepared in accordance with the latest accounting standards issued by the Ministry of Finance, reflecting the company's financial position, operating results, and cash flows accurately[127]. - The accounting period for the financial report is from January 1, 2023, to June 30, 2023[128]. - The company uses RMB as its accounting currency[130]. - The company follows the accounting treatment methods for mergers under common control and non-common control, ensuring proper recognition of goodwill and investment income[130]. - The consolidated financial statements are based on the financial statements of the parent company and its subsidiaries, prepared in accordance with the relevant accounting standards[132]. - The company recognizes joint arrangements and applies appropriate accounting treatments for joint operations and joint ventures[134].

康美药业股份有限公司 第九届监事会第四次会议决议公告 本公司监事会及全体监事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 康美药业股份有限公司（以下简称公司）第九届监事会第四次会议于 2023 年 8 月 17 日以现场表决方式召开，会议通知已按照《公司章程》规定提前 10 日 以通讯方式、电话方式向公司各位监事发出，会议应参加表决监事 3 名，实际参 加表决监事 3 名。本次会议由监事会主席高燕珠女士主持，会议的召集、召开程 序符合《公司法》《证券法》及《公司章程》的规定。会议审议通过以下议案： 一、审议通过《公司 2023 年半年度报告及摘要》 表决结果：赞同票 3 票，反对票 0 票，弃权票 0 票。 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《康美药业 2023 年半年度报告及摘要》。 特此公告。 证券代码：600518 证券简称：ST康美 编号：临2023-029 康美药业股份有限公司监事会 二〇二三年八月十九日 1 ...

证券代码：600518 证券简称：ST康美 编号：临2023-028 具体内容详见公司于同日在上海证券交易所网站（www.sse.com.cn）披露的 《康美药业 2023 年半年度报告及摘要》。 特此公告。 康美药业股份有限公司董事会 二〇二三年八月十九日 1 康美药业股份有限公司 第九届董事会第四次会议决议公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 康美药业股份有限公司（以下简称公司）第九届董事会第四次会议于 2023 年 8 月 17 日以现场表决方式召开，会议通知已按照《公司章程》规定提前 10 日 以通讯方式、电话方式向公司各位董事发出，会议应参加表决董事 9 名，实际参 加表决董事 9 名。本次会议由董事长赖志坚先生主持，公司全体监事和部分高级 管理人员列席了会议，会议的召集、召开程序符合《公司法》《证券法》及《公 司章程》的规定。会议审议通过以下议案： 一、审议通过《公司 2023 年半年度报告及摘要》 表决结果：赞同票 9 票，反对票 0 票，弃权票 0 票。 ...

证券代码：600518 证券简称：ST康美 编号：临2023-027 康美药业股份有限公司 关于公司涉及重大诉讼的结果公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 是否会对上市公司损益产生负面影响：公司 2022 年度已根据会计准则相 关规定，基于审慎性原则，依据一审判决结果，以康美中药城、新世界商贸、世 纪国药被抵押的不动产账面价值为限计提未决诉讼预计负债共计 60,916.28 万 元，减少公司 2022 年度归属于上市公司股东的净利润 60,916.28 万元。本判决 对公司 2023 年度利润具体影响以案件最终执行情况为准。公司将继续保留法律 权利，依据相关规定，维护公司及股东的合法权益，及时履行信息披露义务。 康美药业股份有限公司（以下简称公司）于今日收到广东省高级人民法院 （2022）粤民终 4309 号《民事判决书》，就渤海国际信托股份有限公司与康美 （亳州）华佗国际中药城有限公司、亳州市新世界商贸有限公司等金融借款合同 纠纷诉讼，作出二审终审判决，具体如下： 一、诉讼的基本情况 3、原告 ...

证券代码：600518 证券简称：ST康美 编号：临2023-026 康美药业股份有限公司关于康美实业 所持公司部分股份将被司法拍卖的提示性公告 本公司董事会及全体董事保证本公告内容不存在任何虚假记载、误导性陈述 或者重大遗漏，并对其内容的真实性、准确性和完整性承担法律责任。 重要内容提示： 本次将被司法拍卖的股份为康美实业投资控股有限公司（以下简称康美 实业）持有的公司无限售流通股 155,290,000 股，占公司总股本的 1.12%。 截至本公告日，康美实业持有公司股份 723,176,677 股，占公司总股本 的 5.21%。若本次司法拍卖成功，不会导致公司控股股东及实际控制人发生变化， 亦不会对公司经营活动产生影响。 目前上述司法拍卖事项尚在公示阶段，后续将涉及竞拍、缴款、股权变 更过户等环节，拍卖结果尚存在不确定性，公司将根据后续进展及时履行信息披 露义务。 康美药业股份有限公司（以下简称公司）今日获知，康美实业管理人将依法 分批公开处置康美实业持有的公司股票，第一批司法拍卖股票标的为康美实业持 有的公司无限售流通股 155,290,000 股，占公司总股本的比例为 1.12%，现将本 次拍卖的情 ...

关 于 对 康 美 药 业 股 份 有 限 公 司 2021 年 度 财 务 报 表 出 具 非 标 准 审 计 意 见 审 计 报 告 所 涉 及 事 项 在 2022 年 度 消 除 情 况 的 专 项 说 明 天 职 业 字 [2023]28693-4 号 日 录 2021 年度财务报表出具非标准审计意见审计报告所涉及事项在 2022 年度消除情况的专项 说明— -1 t and the first and the first of the first 关于对康美药业股份有限公司 2021 年度财务报表出具非标准审计意见审计报告 所涉及事项在 2022年度消除情况的专项说明 天职业字[2023]28693-4 号 康美药业股份有限公司全体股东: 我们接受委托,审计了康美药业股份有限公司(以下简称"康美药业"或"公司")2022 年度的财务报表,并出具了标准无保留意见的《审计报告》（天职业字[2023]28693 号）。 康美药业 2021 年度财务报表业经本所审计,并由本所出具了带强调事项段的无保留意见的 《审计报告》（天职业字[2022]25396 号）（以下简称"上期审计报告"）。根据《监管规 则适 ...

Financial Performance - The company reported a net profit of -2,688,674,014.61 CNY for 2022, a decrease of 133.96% compared to the previous year[4]. - Total operating revenue for 2022 was 4,180,150,329.54 CNY, representing a slight increase of 0.67% from 2021[17]. - The net cash flow from operating activities was -749,961,986.24 CNY, a decline of 450.11% compared to the previous year[17]. - As of the end of 2022, the total assets amounted to 15,111,759,138.19 CNY, down 5.87% from the end of 2021[17]. - The company's net assets attributable to shareholders decreased by 30.01% to 6,947,130,703.24 CNY by the end of 2022[17]. - The company plans no profit distribution or capital reserve transfer for 2022[4]. - The company's undistributed profits reached -26,004,732,013.55 CNY by the end of 2022[4]. - The basic earnings per share for 2022 was -0.19 CNY, a decrease of 133.33% compared to 0.57 CNY in 2021[18]. - The diluted earnings per share for 2022 was also -0.19 CNY, reflecting the same percentage decrease of 133.33% from the previous year[18]. - The net profit attributable to shareholders for Q4 2022 was -1,802,903,818.18 CNY, with a total annual net profit of -1,690,774,213.81 CNY across all four quarters[19]. - The operating revenue for Q4 2022 reached 1,458,342,620.92 CNY, contributing to a total annual revenue of approximately 4.18 billion CNY[19]. - The weighted average return on equity for 2022 was -31.87%, an improvement of 88.52% from -120.39% in 2021[18]. - The net cash flow from operating activities for Q4 2022 was -412,997,081.86 CNY, indicating ongoing cash flow challenges[19]. - Non-recurring gains and losses for 2022 totaled -1,180,124,269.62 CNY, significantly impacting the overall financial performance[21]. Business Strategy and Operations - The company is focusing on the traditional Chinese medicine sector, leveraging its integrated operational advantages and strong product quality to capture market opportunities[22]. - The management has implemented strategic adjustments to enhance operational stability and compliance, aiming for sustainable growth in the core business[22]. - The company is committed to innovation and collaboration in the traditional Chinese medicine field, aligning with national health initiatives and increasing consumer demand[22]. - The company signed a strategic cooperation agreement with the government of Dingxi City to promote the healthy development of the traditional Chinese medicine industry, focusing on planting, processing, and storage of medicinal materials[23]. - The company established a new display center for fresh-cut traditional Chinese medicinal materials, which is expected to reduce logistics and procurement costs for pharmaceutical companies by improving quality levels[23]. - The company launched a new version of the "Kangmei Pharmacy Mall" mini-program to provide precise procurement services for wholesale pharmaceutical companies[24]. - The company participated in major trade exhibitions, showcasing its core products such as traditional Chinese medicinal pieces and ginseng, which received widespread recognition[24]. - The company formed seven special working groups to focus on key projects, including resource integration and sales business projects, to achieve its annual strategic goals[27]. - The company improved its internal control system by hiring a third-party consulting firm to optimize and rectify internal control deficiencies, resulting in the creation of the "Kangmei Pharmaceutical Internal Control Manual (2022)"[28]. - The company was recognized as one of the "Stable and Qualified Enterprises" in product quality by a national magazine, enhancing its brand reputation[25]. - The company established a long-term cooperation relationship with Shandong Zhongping Pharmaceutical Co., focusing on standardized planting bases for medicinal materials[24]. - The company’s products received multiple awards, including recognition as "High-tech Products" in Guangdong Province, enhancing its market competitiveness[26]. - The company actively engaged in cultural brand building, aiming to enhance its economic strength through cultural initiatives and value creation[25]. Research and Development - The company has built a 3,000 square meter research and development platform for traditional Chinese medicine, which includes various functional modules for pharmacological research and high-throughput sequencing[34]. - The joint venture company focused on developing traditional Chinese medicine formula granules and health products, resulting in the application of two national standards, with one officially published[35]. - The company launched a new strategic development plan in November 2022, focusing on becoming a leading brand in traditional Chinese medicine with a comprehensive service model[36]. - The traditional Chinese medicine segment is the company's core pillar, with over 1,000 types of products and more than 20,000 specifications currently in production[37]. - The company has verified 113 standard varieties of traditional Chinese medicine (TCM) formula granules, successfully filed 81 varieties, and achieved mass production of 113 varieties with 358 batches as of December 31, 2022[39]. - The company has applied for 84 technology patents, with 56 granted, including 13 invention patents and 43 utility model patents as of December 31, 2022[38]. - The company is committed to improving user data collection to better understand market needs and product effectiveness[88]. - The company is investing heavily in R&D, with a budget increase of 25% for new technology development[138]. Market Expansion and Sales - The company has signed contracts with over 1,000 medical institutions, serving a total of 8.24 million patient visits as of December 31, 2022[38]. - The company has developed a smart pharmacy model that integrates online and offline services, enhancing user experience and optimizing prescription review processes[38]. - The company is actively participating in the revision of national TCM standards and has established multiple industry standards for TCM products[40]. - The company aims to strengthen brand promotion and expand the influence of its proprietary TCM products, focusing on high-demand therapeutic areas[41]. - The company is developing a three-in-one medical and health platform that integrates chain health hospitals, TCM clinics, and rehabilitation departments in collaboration with various medical institutions[42]. - The company has established a nationwide layout of traditional Chinese medicine markets through self-construction and acquisitions, including Anhui Bozhou, Puning, Gansu, and Xining[43]. - The company is transitioning from a single rental and sales model to an integrated operation model, focusing on online and offline integration, with recent strategies including tailored approaches for each market[43]. - The health products segment includes successful development of various ginseng products, with plans to enhance R&D capabilities and expand the product series to meet diverse consumer needs[44]. - The pharmaceutical commercial segment is a major revenue contributor, with a focus on optimizing supply chain management and expanding into high-margin products[45]. - The company is positioned as a leading player in the traditional Chinese medicine industry, with a comprehensive operational model and strong integration capabilities[49]. - The company operates nine production bases across multiple provinces, capable of producing over 1,000 varieties and more than 20,000 specifications of traditional Chinese medicine products[49]. - The company has established strategic partnerships with major e-commerce platforms like Tmall and JD.com, enhancing its online sales presence[54]. - The company has developed 21 high-quality traditional Chinese medicine pieces recognized as high-tech products in Guangdong Province[51]. Corporate Governance and Compliance - The company has implemented a comprehensive internal control system to address deficiencies and enhance risk management[168]. - The company has maintained a strict quality control system, ensuring no major quality safety incidents occurred during the year[170]. - The company achieved ISO management system certifications, including ISO9001, ISO14001, and ISO45001, reinforcing its commitment to quality management[170]. - The company has enhanced financial control by refining financial management systems and improving fund management across subsidiaries[170]. - The company has established a three-in-one mixed performance evaluation system to enhance management performance and align it with organizational goals[168]. - The company has committed to maintaining independence in assets, personnel, finance, governance, and business operations as per the commitment letter from its controlling shareholder[132]. - The company organized independent director and supervisory board field investigations to enhance understanding of subsidiary operations and provide management suggestions[129]. - The company actively communicates with investors to ensure transparency and fairness in information disclosure[131]. - The company has implemented a third-party professional agency to optimize internal control and rectify deficiencies[129]. - The company has proposed to increase the expected amount of daily related transactions for 2022, indicating ongoing operational needs[157]. Social Responsibility - The company invested over CNY 1.4 million in healthcare resources for grassroots regions, enhancing public health services[195]. - The company supported 1,079 registered poor households in Yunnan Province, creating approximately 8,360 job opportunities, with an average annual income increase of CNY 3,000 per person[193]. - The company contributed CNY 697,100 to poverty alleviation and rural revitalization projects, with CNY 600,900 in cash and CNY 96,200 in material donations[191]. - Over 8,300 students from Jieyang were assisted in pursuing higher education through the Jieyang University Student Foundation, promoting local employment and entrepreneurship[194]. - The company plans to leverage its full industry chain advantages in traditional Chinese medicine to further enhance corporate social responsibility and promote local economic development[196]. Legal and Regulatory Issues - The company has a significant legal case involving a financial loan dispute, with a first-instance judgment requiring it to pay approximately 2.82 billion CNY, impacting its net profit for 2022 by 609.16 million CNY[124]. - The company received administrative penalties from the China Securities Regulatory Commission, with fines totaling 2 million yuan for several executives due to inaccurate disclosures[150]. - The Shanghai Stock Exchange publicly reprimanded the company for inaccurate earnings forecasts in 2019 and 2020, leading to disciplinary actions against key executives[150].